In this issue:
Validation of the AJCC 8th edition staging of patients with metastatic cutaneous melanoma treated with ICIs
BRAF/MEK inhibitors + ICIs for metastatic melanoma
Bevacizumab + carboplatin + paclitaxel in patients with previously untreated advanced MM
Chronic irAEs following adjuvant anti–PD-1 therapy for high-risk resected melanoma
Efficiency of detecting new primary melanoma in a high-risk clinic
Multiple primary melanoma incidence trends over five decades
Five-year survival in patients with nodular and superficial spreading melanomas
ctDNA in patients with advanced melanoma treated with dabrafenib or dabrafenib + trametinib
BRAF, NRAS and TERT promoter mutations among patients with cutaneous melanoma
Patient-reported outcome and experience measures in melanoma registries
Please login below to download this issue (PDF)